Canada
· Delayed Price · Currency is CAD BetterLife Pharma Company Description
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada.
It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections.
The company’s products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders.
It is also developing MM-003, which has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream that has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia.
The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019.
BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Ahmad Doroudian |
Contact Details
Address: 1275 West 6th Avenue Vancouver, British Columbia V6H 1A6 Canada | |
| Website | abetterlifepharma.com |
Stock Details
| Ticker Symbol | BETR |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | February - January |
| Reporting Currency | CAD |
| ISIN Number | CA08772P2026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ahmad Doroudian Ph.D. | Founder, Chief Executive Officer and Chairman |
| Moira Ong C.A., CPA, CA, CFA | Chief Financial Officer |
| Dr. Hooshmand Sheshbaradaran Ph.D. | Chief Operating Officer |
| Dr. Stephen Sangha | Corporate Development Advisor |
| Scott Rudge Ph.D. | Head of CMC |
| Anthony Calandra Ph.D. | Head of Regulatory |
| Dr. Abdi Ghaffari Ph.D. | Head of Preclinical and Toxicology |